SEC EDGARAUG 52 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.09 ($512.49–$520.49, $4.91M total) across 9 trades on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · ROTHBLATT MARTINE A

Published Aug 5, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$UTHR

Neutral

medium confidence

Mentioned

$UTHR

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$UTHRNeutralLow

Why it matters

The disclosed sale provides a fresh, timestamped datapoint on insider activity, but it does not disclose any new operational or financial information about United Therapeutics.

Market read

Traders may briefly reassess sentiment around UTHR due to insider selling, but the 10b5-1 framing reduces fundamental inference.

What to watch

Indirect holdings and multiple small trades can reduce interpretability; traders should confirm whether there are concurrent filings (other insiders, buybacks, or material corporate news) before trading the signal.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-05, covering sales executed 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, reported by its CEO chairperson via an indirect holding structure.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$UTHRNeutralMedium confidence

Context

United Therapeutics Form 4 shows CEO chairperson sold $4.9M of UTHR shares via a 10b5-1 plan at $512.49 to $520.49 on 2026-08-04.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-through only if other news coincides.

Evidence & confidence

The filing is primary-source and time-stamped, but it is explicitly under a pre-arranged 10b5-1 plan and does not include new company performance or guidance.

Market effects

Sector

Minimal; insider sale in a single large-cap biotech is unlikely to reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 sales often reflect scheduled liquidity rather than bearish views, so the market may overreact if it treats it as discretionary selling.

Key entities

issuer
United Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
insider
ROTHBLATT MARTINE A
Chairperson and CEO reporting the sale under a 10b5-1 plan.

Read at source ← All news

SEP 11

$UTHRHigh

United Therapeutics Moves to Complete Its $2 Billion Buyback, Betting the Market Is Underpricing Its Pipeline

United Therapeutics (UTHR) announced a $477.6M accelerated share repurchase agreement with Citibank, completing its $2B buyback program. CEO Martine Rothblatt stated the move reflects confidence in the company's undervalued pipeline. The company has returned $4B to shareholders in 2.5 years.

biobuzz.io2 min

SEP 11

$UTHRHigh

United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?

United Therapeutics (UTHR) committed $477.6M to a share repurchase, part of its $2B authorization. The company has $3.8B in cash and investments, with pending FDA reviews for ralinepag and Nebulized Tyvaso. Q2 revenue declined 2% to $783.3M, with Tyvaso revenue down 4%. The buyback's impact on shareholder value depends on pipeline success and cash generation.

insidermonkey.com2 min

SEP 10

$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min

SEP 9

$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min

SEP 9

$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min

SEP 8

$UTHRHighAI 8/10

United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi

United Therapeutics (UTHR) agreed to repurchase $477.6M of its common stock through an accelerated share repurchase with Citi. The company will pay upfront and receive an initial 719,376 shares, with final count based on average daily VWAP. Settlement is expected in Q4 2026.

tradingview.com1 min